Capmatinib

Evidence Level: L5

Predicted Indications: 2

Capmatinib

Pharmacist Assessment Report

Capmatinib: From MET-Driven Cancer Treatment to Rheumatoid Arthritis

One-Sentence Summary

Capmatinib is a selective MET inhibitor and a kinase inhibitor, marketed in India as Rahika. The TxGNN model predicts it may be effective for rheumatoid arthritis, but there are currently no clinical trials and only 1 general review publication with no RA-specific data. This prediction is computational only.

Quick Overview

Item	Content
Original Indication	Not stated in the available India license data (the drug is known as a MET inhibitor for MET-altered cancers)
Predicted New Indication	Rheumatoid arthritis
TxGNN Prediction Score	0.9945
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (2 of 2) – CDSCO approval status is not included in this data
Number of Listed Products	2 (valid: 2)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the compiled data. Based on known information, capmatinib is a selective MET inhibitor. MET signaling has been implicated in synovial inflammation and angiogenesis in rheumatoid arthritis, so a mechanistic rationale is plausible.

However, the only linked publication is a general review of FDA-approved small-molecule kinase inhibitors, and it contains no RA-specific data for capmatinib. The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. The link between the original use (oncology) and RA is therefore hypothesis-level only.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
33513356	2021	Review	Pharmacological Research	General update on FDA-approved small-molecule protein kinase inhibitors; no RA-specific data for capmatinib

India Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
199516	Rahika 150mg Tablet	Strip of 12 tablets	Not stated in the available data
199517	Rahika 200mg Tablet	Strip of 12 tablets	Not stated in the available data

Both products are single-ingredient, valid, oral tablets manufactured by Novartis India Ltd.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (MET tyrosine kinase inhibitor)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Drug Interactions: 100 interactions were identified in the interaction database; 20 were reviewed here. Main ones by severity:
- Major: Dexamethasone, Clarithromycin
- Moderate: Metformin, Alosetron, Loperamide, Aprepitant, Empagliflozin, Glycerol phenylbutyrate, Methylnaltrexone, Metreleptin, Naldemedine, Naltrexone
- Minor: Rabeprazole, Dexlansoprazole, Esomeprazole, Fidaxomicin, Lansoprazole, Naloxegol, Omeprazole, Pantoprazole
Cardiac signal: A published case report describes cardiac toxicity from a pharmacokinetic interaction involving crizotinib, another MET/ALK kinase inhibitor. This is a class-level caution rather than capmatinib-specific evidence, but cardiac safety should be evaluated carefully.
Developmental risk: MET signaling is involved in craniofacial development, so inhibition may carry teratogenic risk.

Please refer to the package insert for warnings and contraindications, as these were not available in the compiled data.

Conclusion and Next Steps

Decision: Hold

Rationale: The rheumatoid arthritis prediction rests only on a high computational score and a plausible but unverified MET-signaling rationale. There are no clinical trials and no RA-specific literature (Evidence Level L5).

To proceed, the following is needed:

Package insert warnings, contraindications, and approved indication text for the India licenses (currently a blocking gap for safety screening)
Detailed mechanism of action data from DrugBank
RA-specific preclinical evidence (for example, MET inhibition in synovial inflammation or arthritis models)
A review of MET-inhibitor safety in the RA population, including cardiac and interaction risks
If pursued at all, heart disease or chemotherapy-toxicity protection is a more evidence-supported research question than RA, though still preclinical
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.